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emphasize that stenting can be an effective
mode of treatment of persistent coronary
artery and graft vasospasm.
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Surgery of Ebstein anomaly
To the Editor:
I read with great interest the article by
Quinonez and colleagues1 concerning sur-
gical treatment of the Ebstein anomaly.
This very informative article underlines the
role of the right ventricle in the outcome of
this congenital anomaly. As my colleagues
and I2 pointed out almost 10 years ago,
impairment of the right ventricle is a major
prognostic factor after surgery for the Eb-
stein anomaly. Inasmuch as medical ther-
apy is difficult to manage, it seemed to us
that the association of a bidirectional cavo-
pulmonary shunt (BCPS) would be helpful
in the early follow-up period. This contin-
ues to be our policy.
The term used by the authors, “1.5-
ventricle,” does not seem to me to be ade-
quate. The flow of the superior vena cava
varies between one third and one half of the
cardiac ouput.3 The 1.5-ventricle concept is
valid when one of the ventricles is anatom-
ically partially deficient.
The article by Quinonez and associates
does not answer a question that arises im-
mediately: what are the indications for the
BCPS? Their definition of “failing right
ventricle” is not clear. In their series, 2
children were free of symptom, whereas,
on the other hand, 3 adult patients were on
the transplantation list. Right ventricular
enlargement could be an indicator, but we
are still looking for quantitative data. In a
study of the right and left ventricular vol-
umes before and after surgery, my col-
leagues and I4 were unable to determine a
threshold value for patients “at risk” and
those that were “safe.” In our experience, a
large atrialized right ventricle (even if ex-
cluded after surgery), a very thin infundib-
ular right ventricular wall, and/or a para-
doxic septal motion are indications for a
superior vena cava derivation. Among 105
patients with Ebstein repair and BPCS, we
did not observe any deleterious effect of
the shunt except for a transient swelling of
the neck in 1 patient.
The BCPS does not solve all of the left
and right ventricular problems. One of the
patients in the authors’ series is not im-
proved and 2 in our own series had to
undergo transplantation.
However, the associated anastomosis is
an excellent additional procedure in pa-
tients with difficult indications.
S. Chauvaud, MD
Cardiovascular Surgery Department
Hôpital Européen Georges Pompidou
Paris, France
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Reply to the Editor:
My colleagues and I thank Dr Chauvaud
for his comments and acknowledge the
contribution of his team to the surgical
treatment of Ebstein anomaly.
The use of the term “1.5-ventricle” was
a semantic choice used to represent an op-
eration, rather than a quantitative or phys-
iologic descriptor. It is widely understood
that diversion of blood flow by a bidirec-
tional cavopulmonary shunt (BCPS) varies
from one third to one half of the systemic
venous return, depending on the patient’s
age.
To decide when to construct a BCPS,
the surgeon has to use his or her judgment
and experience and take into consideration
the patient’s clinical condition, echocardio-
graphic data, magnetic resonance imaging
data (if available), preoperative and intra-
operative hemodynamic data, and the intra-
operative morphologic appearance of the
right ventricle. The status of the left ven-
tricle is also very important. Our series is
too limited to advise as to the specific in-
dications of a BCPS in Ebstein anomaly,
yet with further experience and follow-up
these will become apparent. It is our im-
pression that it is only needed in a few
selected cases.
The term “failing right ventricle” is de-
liberately general. It may describe a right
ventricle that cannot sustain the circulation
after cardiopulmonary bypass; it may de-
scribe a right ventricle that is severely dys-
functional or dilated on echocardiography,
magnetic resonance imaging, or intraoper-
ative inspection; or it may describe a right
ventricle with a large atrialized component,
a thin wall, and paradoxical septal motion,
as pointed out by Dr Chauvaud. In any of
these circumstances, the patient may be
free of symptoms. The underlying diffi-
culty arises in the precise quantification of
right ventricular function by the currently
available methods. We are exploring the
use of magnetic resonance imaging to bet-
ter describe and quantitate the morphology
and function of the right ventricle.
Luis G. Quinonez, MD
University of Alberta Hospital
Edmonton, Alberta, Canada
doi:10.1016/j.jtcvs.2007.07.018
The conduct of experimental
circulatory arrest: The search for
clinical relevance
To the Editor:
I read with great interest the excellent
laboratory study by Dr Ananiadou and
colleagues1 detailing the neuroprotective
effect of profound hypothermia at 10°C
after 75 minutes of circulatory arrest in
an acute porcine model (N  12). The
described neuroprotective mechanism
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may involve antiapoptotic effects. The
discussion about this study focused on
the neuroprotective balance between the
degree of hypothermia and the duration
of circulatory arrest.1
An important consideration is that the
75-minute duration of circulatory arrest
in this animal study exceeds the typical
clinical range of minutes (30 –50 min-
utes).2-4 Why not study the effects of
profound hypothermia in an experimental
model that includes clinically relevant
durations of circulatory arrest? Why not
study brain apoptosis during profound
hypothermia at time intervals of 10 min-
utes within the clinical range to calibrate
the degree of hypothermia with the dura-
tion of ischemia? The answers to this
series of questions would provide addi-
tional laboratory evidence that could per-
haps guide clinical conduct of hypother-
mia for optimal neuroprotection.
This kind of pitfall may be a theme in
experimental circulatory arrest: The con-
duct of hypothermic circulatory arrest in
the laboratory setting is significantly dif-
ferent from that in the clinical setting. As
a consequence, the laboratory findings
are diluted in translation, resulting in a
laboratory– clinical divide that may slow
progress toward the optimal clinical con-
duct of circulatory arrest.
Perhaps it is time for the development
of guidelines for the laboratory study of
circulatory arrest and regional cerebral
perfusion, given the considerable current
controversy in infant perfusion manage-
ment.2-4 To my knowledge, no such
guidelines have been published. The
guidelines could follow a series of delib-
erations among both clinical and labora-
tory experts in this area to develop an-
swers to questions such as the following:
1. What is the recommended study in-
terval of circulatory arrest?
2. What depths of hypothermia should
be studied at which durations of cir-
culatory arrest?
3. What neuroprotective interventions
require further laboratory study in a
clinically relevant model?
4. How should a particular neuropro-
tective intervention best be studied
in the laboratory for maximal clini-
cal utility?
5. Which is the most clinically rele-
vant laboratory model of regional
cerebral perfusion?
6. Which are the most important ques-
tions for further study with respect
to optimizing the practice of re-
gional cerebral perfusion?
I congratulate Dr Ananiadou and col-
leagues1 on their excellent study that has
raised many thought-provoking questions.
I look forward to their feedback and the
ongoing progress in this area.
John G. T. Augoustides, MD, FASE
Department of Anesthesiology and
Critical Care
Hospital of the University of Pennsylvania
Philadelphia, Pa
Financial Support: Department of Anesthesiology
and Critical Care Hospital of the University of
Pennsylvania.
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Reply to the Editor:
Although the deleterious effects of pro-
longed exposure to cardiopulmonary by-
pass on brain function and structure have
been demonstrated, neuroprotective strate-
gies, particularly deep hypothermia and
circulatory arrest (DHCA), remain an issue
of debate. This is related in part to the gap
between the experimental understanding of
brain injury and the clinical application of
various neuroprotective strategies. As sug-
gested by Dr Augoustides, this gap can be
attributed to the lack of clinically relevant
guidelines for effective laboratory study of
circulatory arrest.
Our goal was to assess one possible
mechanism of neuronal injury after DHCA.
Because apoptosis seems to involve a sub-
tle and complex cascade of events, the par-
adigm applied, although not totally clini-
cally relevant, would allow a robust
response for assessment. Further study is
clearly warranted to unravel relevant mech-
anisms and sensitive markers, which in
turn would allow us to appreciate the po-
tential clinical relevance of these experi-
mental findings. Dr Augoustides makes a
valid point for the need to develop appro-
priate guidelines that would enhance this
investigative process.
Evaluating various strategies in animal
studies to determine clinical feasibility has
been limited to large-animal models (por-
cine, canine, and ovine). These are expen-
sive, demanding, and usually performed
without neuropsychologic assessment.
Each model system, however, from cell
cultures to rats, large animals, and ulti-
mately clinical trials, has its advantages
and disadvantages, and its place in these
investigations.
Most animal models require an ex-
tended period of arrest to produce a repro-
ducible level of neuronal injury that would
facilitate elucidating the mechanisms of in-
jury and efficacy of neuroprotective inter-
ventions. Many large animal models re-
quire DHCA for at least 90 to 120 minutes
to demonstrate neurologic deficits.1,2 Al-
though such prolonged DHCA intervals
might not be considered clinically realistic,
they may be more appropriate for demon-
strating the molecular pathways behind
acute neuronal injury and thus modes of
intervention.
Study of a neuroprotective strategy
includes the appropriate selection of an
animal model and functional indices. The
model is selected with respect to the rel-
evance and feasibility of assessing the
parameters of interest. Investigations of
promising neuroprotective methods re-
quire validation (validation study), use in
experimental settings to optimize cere-
bral protection during cardiopulmonary
bypass and DHCA (performance study),
and test during routine cardiac surgery
(clinical study).
A clearer understanding of the conse-
quences of DHCA will be pivotal in clin-
ical decision-making, including when to
initiate circulatory arrest and the appro-
priate interval. Delayed cell death is of
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